ENTITY

SK Bioscience (302440 KS)

176

Analysis

Health Care • South Korea

SK Bioscience Co.,Ltd. operates biopharmaceutical businesses. The Company produces vaccines, sky cellflu prefilled syringes, sky cellflu quadrivalent prefilled syringes, varicella drugs, and other related products. SK Bioscience markets its products throughout South Korea.

more

Refresh

Exchange Announcement • 19 Nov 2024 17:53

Material Business Matters Related to Investment Decisions(Phase 3 CTA application for 21valent Pneumococcal Conjugate Vaccine, GBP410 in EU (Part I, Part II))

Exchange Announcement • 28 Oct 2024 16:16

Material Business Matters Related to Investment Decisions(Phase 3 IND application for 21valent Pneumococcal Conjugate Vaccine, GBP410 in Korea)

Exchange Announcement • 28 Oct 2024 15:40

Material Business Matters Related to Investment Decisions(21ê° íë ´êµ¬ê· ë°±ì (GBP410)ì íêµ ì 3ì ìììíê³í (IND) ì ì²)

Exchange Announcement • 24 Oct 2024 17:35

Organization of Investor Relations Event

Exchange Announcement • 24 Oct 2024 17:25

Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.40.5

x